Bupropion for Methamphetamine Cravings: XL vs SR Formulation
For methamphetamine cravings, use bupropion SR 150 mg twice daily rather than XL 150 mg once daily, because all clinical trials demonstrating efficacy in methamphetamine use disorder employed the SR formulation at a total daily dose of 300 mg (150 mg twice daily), and the XL formulation has never been studied for this indication. 1, 2, 3, 4
Evidence Base for Bupropion in Methamphetamine Use Disorder
Efficacy Profile
Bupropion SR 150 mg twice daily (total 300 mg/day) shows benefit specifically in individuals with light-to-moderate baseline methamphetamine use (defined as methamphetamine use on ≤18–29 of the past 30 days), with one trial demonstrating significantly increased abstinence weeks in this subgroup (p<0.0001 among males with lower baseline use). 1
A post-hoc analysis revealed that among light users (0–2 methamphetamine-positive urines at baseline), bupropion SR produced a statistically significant effect on methamphetamine-free weeks (OR=2.81,95% CI=1.61–4.93, p<0.001), whereas no effect was observed in heavier users. 2
In the overall methamphetamine-dependent population without stratification by baseline use severity, bupropion SR has not demonstrated statistically significant superiority over placebo in multiple randomized controlled trials. 3, 4
Combination Therapy Evidence
The most robust recent evidence comes from the ADAPT-2 trial, which evaluated injectable extended-release naltrexone plus oral extended-release bupropion (not bupropion alone), showing a 27.1% increase in probability of testing methamphetamine-negative over 12 weeks (95% CI, 13.2%–41.1%, p<0.001) compared to 11.4% with placebo. 5
This combination approach is currently under investigation in an Australian trial using oral naltrexone 40 mg plus bupropion 450 mg daily in divided doses. 6
Why SR Formulation Is Required
Dosing Schedule Differences
Bupropion SR requires twice-daily dosing (150 mg in the morning, 150 mg before 3 PM) to achieve the 300 mg total daily dose used in all methamphetamine trials. 7, 8
Bupropion XL is dosed once daily in the morning and is FDA-approved only for major depressive disorder and seasonal affective disorder at 150–300 mg once daily. 8
Although XL and SR formulations deliver comparable total daily exposure when dosed at equivalent amounts, they are not interchangeable in their dosing schedules, and each formulation must follow its specific FDA-approved timing to maintain safety and efficacy. 7
Clinical Trial Precedent
Every published randomized controlled trial of bupropion for methamphetamine use disorder employed the SR formulation at 150 mg twice daily (total 300 mg/day), not the XL formulation. 1, 2, 3, 4
The XL formulation has been compared to SR only for smoking cessation and depression, where therapeutic equivalence was demonstrated, but no studies have evaluated XL for methamphetamine cravings or use disorder. 9
Practical Implementation
Initiation Protocol
Start bupropion SR 150 mg once daily in the morning for the first 3–4 days, then increase to 150 mg twice daily (morning and before 3 PM) if tolerated, for a maximum of 300 mg per day in divided doses. 7
The second daily dose must be administered before 3 PM to reduce insomnia risk, as bupropion's activating properties can interfere with sleep when taken late in the day. 7, 8
Early Monitoring (First 1–2 Weeks)
Assess for neuropsychiatric adverse effects including suicidal ideation, agitation, irritability, unusual behavioral changes, worsening depression, hostility, and impulsivity, as the highest risk period is the first 1–2 months of therapy. 7
Monitor for common adverse effects: loss of appetite, insomnia, anxiety, agitation, dry mouth, headache, nausea, constipation, and tremor. 7
Treatment Duration and Response Assessment
A full therapeutic trial requires 4–8 weeks at the target dose of 300 mg/day; reassess treatment adequacy at 6–8 weeks. 7
Medication adherence is critical: in one trial, only 47% of participants achieved protocol-defined adherence (detectable bupropion in ≥50% of urine samples), and adherence was associated with significantly higher abstinence rates (54% vs 18%, p=0.018). 3, 4
Absolute Contraindications
History of seizure disorders or conditions that lower seizure threshold (e.g., stroke, brain metastases, eating disorders such as anorexia nervosa or bulimia nervosa) is an absolute contraindication, as bupropion carries approximately 0.1% seizure risk at therapeutic doses. 7, 8
Current or recent (within 14 days) use of monoamine oxidase inhibitors. 7, 8
Abrupt discontinuation of alcohol or benzodiazepines. 7
Clinical Context and Limitations
Medication Adherence Challenge
Low medication adherence is a major limitation in bupropion trials for methamphetamine use disorder, with adherence rates as low as 32–47% in some studies, which may obscure true efficacy. 3, 4
Plasma bupropion/hydroxybupropion levels can be used to objectively assess adherence when available. 3
Psychosocial Therapy Remains Essential
All bupropion trials for methamphetamine use disorder included concurrent behavioral interventions (contingency management, cognitive behavioral therapy, or group psychotherapy), and psychosocial therapy remains the mainstay of treatment. 1, 2, 3, 4
Contingency management alone or combined with community reinforcement approach has superior efficacy compared to treatment-as-usual for stimulant use disorders, with moderate-to-high strength of evidence. 10
Consideration of Combination Therapy
For patients who do not respond adequately to bupropion SR alone, consider the naltrexone-bupropion combination based on ADAPT-2 trial results, though the injectable naltrexone formulation used in that trial may not be readily available globally. 5, 6
The naltrexone-bupropion combination is contraindicated in patients receiving concurrent opioid therapy, as it can precipitate withdrawal and diminish analgesic effect. 7
Dose Adjustments for Special Populations
Moderate-to-severe renal impairment: reduce total daily dose by 50%. 7, 8
Moderate-to-severe hepatic impairment (Child-Pugh score 7–15): maximum dose is 150 mg every other day. 8
Mild hepatic impairment (Child-Pugh score 5–6): consider reducing dose and/or frequency. 8
Common Pitfall to Avoid
Do not prescribe bupropion XL 150 mg once daily for methamphetamine cravings simply because it is a convenient once-daily formulation. The evidence base is specific to bupropion SR 300 mg/day in divided doses, and using XL at a subtherapeutic total daily dose (150 mg) or without the twice-daily dosing schedule studied in clinical trials represents off-label use without supporting data. 1, 2, 3, 4